In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer

Ramona Rudalska,Daniel Dauch,Thomas Longerich,Katherine McJunkin,Torsten Wuestefeld,Tae-Won Kang,Anja Hohmeyer,Marina Pesic,Josef Leibold,Anne von Thun,Peter Schirmacher,Johannes Zuber,Kh Weiss,Scott Powers,Nisar P. Malek,Martin Eilers,Bence Sipos,Scott W. Lowe,Robert Geffers,Stefan Laufer,Lars Zender

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer

2014

An in vivo RNAi dropout screen identifies Mapk14 as a new mediator of sorafenib resistance in hepatocellular carcinoma, and Mapk14 inhibition both improves sorafenib therapy and restores sensitivity to sorafenib-resistant tumors.

Keywords:

Immunology
Liver cancer
MAPK14
In vivo
Hepatocellular carcinoma
Sorafenib
RNA interference
Signal transduction
Mediator
Medicine
Small hairpin RNA
Blockade
Gene silencing
Drug resistance

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

185

Citations